Literature DB >> 26408402

Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia.

Katja Seipel1, Miguel Teixera Marques2, Marie-Ange Bozzini2, Christina Meinken2, Beatrice U Mueller2, Thomas Pabst3.   

Abstract

PURPOSE: In acute myeloid leukemia (AML), the transcription factors CEBPA and KLF4 as well as the universal tumor suppressor p53 are frequently deregulated. Here, we investigated the extent of dysregulation, the molecular interactions, and the mechanisms involved. EXPERIMENTAL
DESIGN: One hundred ten AML patient samples were analyzed for protein levels of CEBPA, KLF4, p53, and p53 modulators. Regulation of CEBPA gene expression by KLF4 and p53 or by chemical p53 activators was characterized in AML cell lines.
RESULTS: We found that CEBPA gene transcription can be directly activated by p53 and KLF4, suggesting a p53-KLF4-CEBPA axis. In AML patient cells, we observed a prominent loss of p53 function and concomitant reduction of KLF4 and CEBPA protein levels. Assessment of cellular p53 modulator proteins indicated that p53 inactivation in leukemic cells correlated with elevated levels of the nuclear export protein XPO1/CRM1 and increase of the p53 inhibitors MDM2 and CUL9/PARC in the cytoplasm. Finally, restoring p53 function following treatment with cytotoxic chemotherapy compounds and p53 restoring non-genotoxic agents induced CEBPA gene expression, myeloid differentiation, and cell-cycle arrest in AML cells.
CONCLUSIONS: The p53-KLF4-CEBPA axis is deregulated in AML but can be functionally restored by conventional chemotherapy and novel p53 activating treatments. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26408402     DOI: 10.1158/1078-0432.CCR-15-1054

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

1.  Krüppel-like Factor 4 Supports the Expansion of Leukemia Stem Cells in MLL-AF9-driven Acute Myeloid Leukemia.

Authors:  Andrew Henry Lewis; Cory Seth Bridges; David Neal Moorshead; Taylor J Chen; Wa Du; Barry Zorman; Pavel Sumazin; Monica Puppi; H Daniel Lacorazza
Journal:  Stem Cells       Date:  2022-08-25       Impact factor: 5.845

2.  miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.

Authors:  Timothy J Molloy; David D Ma; Thi Thanh Vu; Friedrich Stölzel; Kristy W Wang; Christoph Röllig; Melinda L Tursky
Journal:  Leukemia       Date:  2020-12-01       Impact factor: 11.528

3.  High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.

Authors:  Jinlong Shi; Huaping Fu; Zhilong Jia; Kunlun He; Lin Fu; Weidong Wang
Journal:  EBioMedicine       Date:  2016-11-22       Impact factor: 8.143

Review 4.  Chromatin-Bound Cullin-Ring Ligases: Regulatory Roles in DNA Replication and Potential Targeting for Cancer Therapy.

Authors:  Sang-Min Jang; Christophe E Redon; Mirit I Aladjem
Journal:  Front Mol Biosci       Date:  2018-03-13

5.  The significance of c.690G>T polymorphism (rs34529039) and expression of the CEBPA gene in ovarian cancer outcome.

Authors:  Bozena Konopka; Lukasz Michal Szafron; Ewa Kwiatkowska; Agnieszka Podgorska; Aleksandra Zolocinska; Barbara Pienkowska-Grela; Agnieszka Dansonka-Mieszkowska; Anna Balcerak; Martyna Lukasik; Anna Stachurska; Agnieszka Timorek; Beata Spiewankiewicz; Mona El-Bahrawy; Jolanta Kupryjanczyk
Journal:  Oncotarget       Date:  2016-10-11

6.  The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.

Authors:  Katja Seipel; Miguel A T Marques; Corinne Sidler; Beatrice U Mueller; Thomas Pabst
Journal:  Cancers (Basel)       Date:  2018-05-31       Impact factor: 6.639

7.  Inducible transgene expression in PDX models in vivo identifies KLF4 as a therapeutic target for B-ALL.

Authors:  Wen-Hsin Liu; Paulina Mrozek-Gorska; Anna-Katharina Wirth; Tobias Herold; Larissa Schwarzkopf; Dagmar Pich; Kerstin Völse; M Camila Melo-Narváez; Michela Carlet; Wolfgang Hammerschmidt; Irmela Jeremias
Journal:  Biomark Res       Date:  2020-09-16

8.  The prognostic significance of nuclear expression of PHF2 and C/EBPα in clear cell renal cell carcinoma with consideration of adipogenic metabolic evolution.

Authors:  Jeong Hwan Park; Minsun Jung; Kyung Chul Moon
Journal:  Oncotarget       Date:  2017-08-04

9.  Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma.

Authors:  Margaret Pain; Huaien Wang; Eunjee Lee; Maya Strahl; Wissam Hamou; Robert Sebra; Jun Zhu; Raymund L Yong
Journal:  Oncotarget       Date:  2017-12-20

10.  Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.

Authors:  Luciana De Luca; Stefania Trino; Ilaria Laurenzana; Daniela Tagliaferri; Geppino Falco; Vitina Grieco; Gabriella Bianchino; Filomena Nozza; Valentina Campia; Francesca D'Alessio; Francesco La Rocca; Antonella Caivano; Oreste Villani; Daniela Cilloni; Pellegrino Musto; Luigi Del Vecchio
Journal:  Cell Death Dis       Date:  2017-06-01       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.